Literature DB >> 8522254

Female urethral adenocarcinoma: evidence for more than one tissue of origin?

M K Dodson1, W A Cliby, P P Pettavel, G L Keeney, K C Podratz.   

Abstract

Adenocarcinoma of the female urethra accounts for 10% of all urethral cancers. Controversy continues to exist over the origin of primary urethral adenocarcinomas. The periurethral (Skene's) glands appear to be the homologues of the male prostate as defined by authors evaluating cadaver-derived periurethral glands pathologically and immunohistochemically (prostate-specific antigen (PSA)). It is traditionally assumed that the origin of female urethral adenocarcinoma is the Skene's gland. However, no one has evaluated a series of primary urethral adenocarcinomas in an effort to scrutinize this assumption. We, therefore, evaluated 13 primary adenocarcinomas of the female urethra comparing histologic and immunohistochemical characteristics. Tumors were classified into two major histologic groups: columnar/mucinous (11) and clear cell (2). Excluding one case, the columnar/mucinous tumors resembled either endometrial or colonic adenocarcinoma. The exception was a case bearing a striking resemblance to prostatic adenocarcinoma. Immunohistochemical results revealed positive PSA staining for this tumor alone. The patient's preoperative serum PSA was elevated, but rapidly declined postoperatively. Based on immunohistochemical findings and the presence of distinct histologic subtypes (columnar/mucinous, clear cell), it appears that female urethral adenocarcinoma has more than one tissue of origin with a minority arising from the Skene's glands.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522254     DOI: 10.1006/gyno.1995.9963

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  [Female prostate cancer?]

Authors:  S Thum; B Haben; G Christ; R Sen Gupta
Journal:  Pathologe       Date:  2017-09       Impact factor: 1.011

2.  Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing.

Authors:  Rohit Mehra; Pankaj Vats; Shanker Kalyana-Sundaram; Aaron M Udager; Michael Roh; Ajjai Alva; Jincheng Pan; Robert J Lonigro; Javed Siddiqui; Alon Weizer; Cheryl Lee; Xuhong Cao; Yi-Mi Wu; Dan R Robinson; Saravana M Dhanasekaran; Arul M Chinnaiyan
Journal:  Am J Pathol       Date:  2014-01-03       Impact factor: 4.307

Review 3.  Adenocarcinoma of the urethra with mucinous features.

Authors:  Arthi Satyanarayan; Lucas Redd; Anthony Dyer; Andrew Wright; Jonathan Walker
Journal:  Rev Urol       Date:  2015

4.  Clear cell adenocarcinoma of a female urethra: A case report and review of the literature.

Authors:  Amel Trabelsi; Soumaya Ben Abdelkrim; Soumaya Rammeh; Wided Stita; Nabil Ben Sorba; Moncef Mokni; Slim Ben Ahmed; Sadok Korbi
Journal:  N Am J Med Sci       Date:  2009-11

Review 5.  Clear cell adenocarcinoma of the urethra: review of the literature.

Authors:  Anthony Kodzo-Grey Venyo
Journal:  Int J Surg Oncol       Date:  2015-01-20

Review 6.  Urethral diverticulum carcinoma in females-a case series and review of the English and Japanese literature.

Authors:  Eabhann O'Connor; Domniki Iatropoulou; Sho Hashimoto; Satoru Takahashi; Daniel Heffernan Ho; Tamsin Greenwell
Journal:  Transl Androl Urol       Date:  2018-08

7.  Brachytherapy for the Conservative Treatment of Female Peri-Urethral Carcinoma.

Authors:  Mickaël Andraud; Manon Kissel; Roger Sun; Elie Rassy; Sophie Espenel; Samir Achkar; Philippe Morice; Christine Haie-Meder; Sébastien Gouy; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

8.  Prolactin promotes a partial recovery from the atrophy of both male and female gerbil prostates caused by castration.

Authors:  Marianna Zanatelli; Simone Jacovaci Colleta; Luiz Henrique Alves Guerra; Fernanda Cristina Alcântara Santos; Rejane Maira Góes; Patricia Simone Leite Vilamaior; Sebastião Roberto Taboga
Journal:  Reprod Biol Endocrinol       Date:  2021-06-22       Impact factor: 5.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.